Crafting a Compelling Pitch to Seasoned Investors & Partners When Your Platform Offers a New Technology Approach in an Existing Field

This session will present strategies from CEOs who have secured major financings (AsherBio $108M Series B; Seismic $101M Series A) for taking your leading-edge company pitch to seasoned investors and partners. Some of the most compelling biotech companies are being established to ’raise the bar” with therapies and platforms that represent next-generation approaches within a landscape of well-established drug modalities such as GPCRs, engineered antibodies for autoimmune diseases, and cytokines (e.g. IL-2). Building and financing this genre of company requires communicating a clear and distinct value proposition and strong positioning in therapeutic areas that already have approved drugs. Your story must stand out in the competitive landscape and set your approach apart from legacy companies that have defined the space for years. Speakers will describe techniques for developing pitches and attracting investors and partners who are deeply knowledgeable in the space.